Citation:

Carvalho, LCR, Lourenco A, Ferreira LM, Branco PS.  2019.  Tofacitinib Synthesis - An Asymmetric Challenge, JAN 31. EUROPEAN JOURNAL OF ORGANIC CHEMISTRY. 2019:615-624., Number 4

Abstract:

Tofacitinib is a Janus activated kinase (JAK) inhibitor approved for the treatment of rheumatoid arthritis and active psoriatic arthritis. Its synthesis normally involves long synthetic sequences due to the chirality associated to the piperidine ring. This review is a comprehensive analysis of the different synthetic methods used to prepare this active pharmaceutical ingredient (API), covering the related journal and patent literature.

Notes:

n/a